Pharmacy Times

AUGUST 10, 2023

Approximately 57% of individuals who were shown a flowchart of the FDA vaccine approval process were very or somewhat likely to recommend a respiratory syncytial virus vaccine to a pregnant family member or friend compared to only 40% of those who were not shown the process.

Vaccines 122

Vaccines Communication FDA 122

Pharmacy Times

NOVEMBER 10, 2022

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, leads a discussion on the challenges subvariants of SARS-CoV-2 present in terms of vaccination and approaching optimal communication to the public surrounding vaccination.

Vaccines 122

Vaccines Communication 122

pharmaphorum

NOVEMBER 19, 2021

The race to find and bring vaccines to market to fight Covid was impressive. It’s been almost a year since the first Covid vaccine was authorised for use. Meanwhile, China and Russia have rolled out state-owned vaccines. Pfizer/BioNTech’s vaccine dominates the market. billion in vaccine sales this year.

Vaccines 137

Vaccines Communication 137

Pharmacy Times

JULY 22, 2022

Pharmacists discuss the impacts of inaccuracy on vaccine hesitancy and offer communication strategies for conversations with patients.

Vaccines 94

Vaccines Communication 94

pharmaphorum

MAY 19, 2022

The likelihood of long COVID symptoms was found to decrease after COVID-19 vaccination, and evidence pointed to an even greater improvement after a second dose. However, the authors say more data is needed before vaccination can be considered a treatment for the condition.

Vaccines 124

Vaccines Immunization Communication 124

European Pharmaceutical Review

MARCH 6, 2023

The first clinical trial of any subunit tuberculosis (TB) vaccine in a temperature-stable form has found that ID93+GLA-SE, a freeze-dried vaccine, was safe. The recombinant subunit vaccine is made from four proteins of Mycobacterium tuberculosis bacteria combined with GLA-SE, an immune-stimulating adjuvant.

Immunization 103

Immunization Vaccines Communication 103

Pharmaceutical Technology

DECEMBER 11, 2022

The US Food and Drug Administration (FDA) has granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against Covid-19 and influenza. The vaccine is intended to prevent two respiratory ailments through a single injection. 5 Omicron sublineages spike proteins.

Vaccines 115

Vaccines FDA Communication 115

Pharmacy Times

AUGUST 14, 2024

Patient fears can be mitigated by pharmacists who use targeted communication strategies to bolster acceptance.

Vaccines 94

Vaccines Communication 94

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

Vaccines 97

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 97

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The post GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA appeared first on Pharmaceutical Technology.

Vaccines 115

Vaccines Communication 115

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. That suggests that patients could get SARS-CoV-2 twice, but also that the current crop of vaccines may not be as effective.

Vaccines 98

Vaccines Communication Immunization 98

pharmaphorum

DECEMBER 17, 2020

Tik Tok is unlikely to spring to mind as a source of reliable information about complex issues, but scientists are using it to fly the flag for COVID-19 vaccines and other health topics. When we talk about vaccines as health professionals, people who are vehemently anti-vaccine can take it out of context for their agenda.

Vaccines 97

Vaccines Communication Immunization 97

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccines 98

Vaccines Immunization Communication 98

Pharmacy Times

OCTOBER 25, 2024

Carrie Koenigsfeld, PharmD, FAPhA, discusses her experience with concerns and perceptions contributing to RSV vaccine hesitancy among older adults, such as safety, efficacy, necessity, awareness, and cost, and she explores how pharmacists can effectively counsel patients and caregivers about RSV vaccines while tailoring communication strategies to (..)

Vaccines 65

Vaccines Communication 65

Pharmafile

JANUARY 23, 2023

Indian biotech company Bharat Biotech plans to launch its new intranasal COVID-19 vaccine iNCOVACC on the 26 January 2023 ‒ the vaccine is the first of its kind to be developed in India. read more

Vaccines 98

Vaccines Communication 98

Pharmafile

MARCH 2, 2023

Yesterday, GSK shared that an advisory committee from the FDA voted in support of its respiratory syncytial virus (RSV) vaccine candidate for older adults. This support is ahead of an official FDA approval for the company’s vaccine. GSK has shared that a final decision is expected to be made by the FDA ahead of the 3 May. read more

Vaccines 98

Vaccines FDA Communication 98

Pharmaceutical Technology

MAY 22, 2023

The Covid-19 pandemic saw a proliferation in novel vaccine technologies being produced rapidly. With the emergence of vaccines came accusations of technology encroachment amongst biotech companies. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vaccines 116

Vaccines Communication 116

Pharmaceutical Technology

JANUARY 31, 2023

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Moderna ’s investigational mRNA vaccine candidate, mRNA-1345, for respiratory syncytial virus (RSV) in adult patients. The investigational mRNA-1345 vaccine uses the same lipid nanoparticles (LNPs) that are also used in the Moderna Covid-19 vaccines.

Vaccines 72

Vaccines FDA Communication 72

Pharmacy Times

MARCH 22, 2025

Pharmacists can empower patient RSV vaccination through strategic communication and personalized care.

Vaccines 50

Vaccines Communication 50

Pharmafile

JANUARY 13, 2023

The FDA, along with Taiwanese medical institutions, have been evaluating Pfizer’s mRNA COVID-19 vaccine, questioning the CDC’s omission of known severe “adverse events of special interest” (AESIs) which appeared in post-vaccination studies. read more. read more.

Vaccines 78

Vaccines FDA Communication 78

Pharmafile

DECEMBER 23, 2022

BioNTech has announced the start of its new first-in-human phase 1 trial for BNT165b1, a candidate from its programme which aims to develop a multi-antigen malaria vaccine.

Vaccines 80

Vaccines Communication 80

Pharmaceutical Technology

APRIL 25, 2023

As the prophylactic landscape for malaria has changed in recent years with vaccine approvals, major issues still remain with ensuring access in remote communities. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements. The Mosquirix vaccine contains two vials.

Vaccines 69

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 69

Pharmaceutical Technology

NOVEMBER 30, 2022

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.

Vaccines 59

Vaccines Communication 59

Omnicell

JANUARY 10, 2023

Director Regional Operations, EnlivenHealth The biggest vaccination campaign in history is underway and scaling fast. COVID-19 vaccines are now being distributed across the USA and administered to an expanding universe of patient populations. And that’s where technology becomes imperative. are preparing for the next phase.

Vaccines 52

Vaccines Omnicell Communication 52

Pharmafile

APRIL 24, 2023

Sanofi has introduced a hepatitis A vaccine for children aged between one to 15 years old in the UK. The vaccine, inactive AVAXIM Junior, will consist of two doses injected intramuscularly six to 36 months apart. It is the most common form of viral hepatitis and the third most common vaccine-preventable infection among travellers.

Vaccines 59

Vaccines Communication 59

Pharmaceutical Technology

MAY 4, 2023

After a winter marked by a rise in hospitalisations due to the RSV, the FDA has granted its first approval for an Respiratory Syncytial Virus (RSV) vaccine to GSK’s Arexvy for adults ages 60 years and above. This vaccine specifically prevents RSV-related lower respiratory tract disease (LRTD).

Vaccines 64

Vaccines FDA Communication Immunization 64

Pharmafile

MARCH 15, 2023

Yesterday, the FDA announced that it has amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech bivalent COVID-19 Vaccine. read more

Vaccines 59

Vaccines FDA Communication 59

Pharmaceutical Technology

JUNE 8, 2023

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.

Vaccines 52

Vaccines Immunization Communication 52

Pharmaceutical Technology

DECEMBER 13, 2022

To develop a vaccine and then get as many people vaccinated as quickly as possible. Advanced monitoring and analysis technology has enabled more than 13 billion COVID-19 vaccinations to be distributed worldwide to date. In an ever-changing environment, more robust and scalable communications solutions are required.

Vaccines 52

Vaccines Communication Documentation 52

Pharmafile

APRIL 28, 2023

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its PREVNAR 20 (20-valent pneumococcal conjugate vaccine) for the prevention of invasive pneumococcal disease (IPD) in infants and children from six weeks to 17 years of age. read more

Vaccines 59

Vaccines FDA Communication 59

Omnicell

SEPTEMBER 5, 2022

Danny Sanchez VP and General Manager, EnlivenHealth® As news emerged about the positive COVID-19 vaccine trial results from Pfizer and its German partner BioNTech, the attention turned to how the vaccine would be distributed and administered to 330 million Americans.

Vaccines 52

Vaccines Documentation Communication 52

Pharmafile

DECEMBER 9, 2022

Pfizer has announced that the FDA has accepted its application for a respiratory syncytial virus (RSV) vaccine for older adults, with the FDA expected to come to a decision by Spring 2023. The FDA will review the application under the priority review programme, meaning the approval timeline should be reduced by four months. read more.

Vaccines 59

Vaccines FDA Communication 59

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59

Pharmafile

APRIL 19, 2023

The FDA has announced its amendment of the emergency use authorisations (EUAs) for the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines in an attempt to simplify the vaccination programme. These amendments mean that: read more

Vaccines 52

Vaccines FDA Communication 52

Pharmaceutical Technology

MARCH 1, 2023

Oragenics and Inspirevax have signed a license agreement to develop the former’s lead intranasal vaccine candidate for Covid-19, NT-CoV2-1. As part of the exclusive international agreement, Oragenics agreed to pursue the vaccine development with the new BDX301 intranasal mucosal adjuvant of Inspirevax.

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

MAY 30, 2023

million government grant from the Flanders Innovation & Entrepreneurship (VLAIO) agency that will be used to fuel the company’s vaccine platform, per a 30 May announcement. The company’s prophylactic yellow fever vaccine is part of its plasmid-launched live attenuated virus (PLLAV) platform. AstriVax has received a €2.5

Vaccines 52

Vaccines Communication 52

Pharmafile

APRIL 27, 2023

GSK has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has shared a positive opinion on its respiratory syncytial virus (RSV) vaccine candidate for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults over the age of 60. read more

Vaccines 52

Vaccines Communication 52